Correction: Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group
Sanjay P. Bagaria(WinnMed), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Dimitri Tzanis(Université Paris Cité), Yvonne Schrage(The Netherlands Cancer Institute), Carol J. Swallow(University Health Network), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Vittorio Quagliuolo(Humanitas University), Kenneth Cardona(Emory University), Ferdinando Cananzi(Humanitas University), Nicholas D. Klemen(Yale University), Marko Novak(Peter MacCallum Cancer Centre), Valerie P. Grignol(Ohio State University Hospital), Giovanni Grignani(Candiolo Cancer Institute), Nita Ahuja(Yale University), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), Jos A. van der Hage(Leiden University Medical Center), Carolyn Nessim(University of Ottawa), Sameer Apte, Daphne Hompes, Raphael E. Pollock(The Ohio State University), Matthew R. Spiegel(Mayo Clinic in Florida), Robert J. Canter(Virginia Tech), Winan J. van Houdt(Diakonessenhuis hospital), Markus Albertsmeier(LMU Klinikum), Emmanuel Gabriel(Mayo Clinic in Florida), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Harini Suraweera(Mount Sinai Hospital), Mark Fairweather(Brigham and Women's Hospital), Martin Almquist(Lund University), Marco Rastrelli(Istituti di Ricovero e Cura a Carattere Scientifico), Alexandra Gangi(Peter MacCallum Cancer Centre), Adriana C. Gamboa(Emory University), Lorenzo Conti(Fondazione IRCCS Istituto Nazionale dei Tumori), Eberhard Stoeckle(Institut Bergonié), Zhou Li(Communication University of China), Elisabetta Pennacchioli(European Institute of Oncology), Sergio Valeri(Università Campus Bio-Medico), Jacek Skoczylas(The Maria Sklodowska-Curie National Research Institute of Oncology), David Gyorki(The University of Melbourne)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k